Multiple Myeloma Clinical Trial
Official title:
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
Primary Objective:
- To determine if there is significant toxicity associated with the administration of
CD34-TK75 transduced donor lymphocytes after allogeneic BMT for relapsed hematologic
malignancies
Secondary Objectives:
- To determine if the patient develops any evidence of anti-leukemic effect from the
administration of CD34-TK75 transduced donor lymphocytes
- To determine if ganciclovir administration to patients who develop Graft versus Host
Disease (GVHD)results in clinical improvement after infusions of CD34-TK75 transduced
lymphocytes.
Sub-Study Objective
The primary purpose is to perform PET imaging of CD34-TK transduced allogeneic donor T cells
in patients who have relapsed hematologic malignancies after allogeneic hematopoietic stem
cell transplantation (SCT). At this time the limited amount of cGMP quality virus produced
by the NGVL will likely permit the imaging of only 3 patients. Consequently our current
objective will be to establish that the TK-expressing cells can be detected by 18FHBG-PET in
patient organs relevant for performing additional studies that are currently in the planning
stages and for which we are working to produce additional virus.
The ultimate objective will be to use the TK substrate 18FHBG to locate the donor T cells
within the recipient as they exert anti-leukemic effects, and the T cells can then be
eliminated in response to in vivo administration of ganciclovir, before morbidity and
mortality from GvHD occurs. We will use the imaging strategy to define patterns of T cell
trafficking in humans pre and post-DLI infusion, and to determine where the cells reside
while they mediate GVL in contrast to GvHD. We expect to obtain in vivo PET imaging markers
predictive of GvHD before clinical symptoms occur.
This is a phase I study of to determine the safety of the administration of lymphocytes,
collected from the bone marrow donor. Donor lymphocytes are often administered in the case
of a relapsed cancer after allogeneic bone marrow transplantation, in the hope to reduce the
amount or size of the relapsed cancer. In this study, we will look for a decrease of the
size of the relapsed cancer.
By inserting genetic material (DNA) into the cells (lymphocytes) collected from the donor,
these cells will be genetically modified and made very sensitive to the killing effects of a
drug called ganciclovir, routinely used in the clinic after bone marrow transplantation to
treat virus infections in transplant patients.
This research study is to determine, if administration of the drug ganciclovir to the
recipient, after intravenous infusion of the genetically modified cells (lymphocytes) into
the recipient, will reduce or even eliminate a life threatening complication of allogeneic
transplantation, called graft versus host disease (GvHD). The drug ganciclovir will kill the
infused genetically modified donor cells (lymphocytes) so they cannot cause GvHD.
In summary, the overall purpose of this research study is to determine, if administration of
a seven day course of the drug ganciclovir to the donor lymphocyte recipient will either
decrease the severity of GvHD, or will decrease the number of cases with life-threatening
GvHD after donor lymphocyte infusions.
This study will also determine if insertion of a small piece of DNA (a small piece of
genetic material), makes these donor lymphocytes opened up and sensitive to the killing
effects of the drug ganciclovir, but at the same time does not harm the lymphocytes' ability
to reduce the amount or size of the cancer in the recipient. The DNA to be inserted into the
donor lymphocytes is transported into these cells by a type of virus called "retrovirus
vector". This retrovirus vector is made so the virus cannot divide (cannot make more of
itself), and cannot make cells or the recipient sick. Retroviruses do, however, allow for
the gene (DNA) they are carrying, to be permanently inserted into the genetic material of
the donor lymphocytes. Therefore, this inserted DNA will persist in the donor lymphocytes
for the life of the lymphocytes.
Finally, this study will also determine if the administration of genetically manipulated
donor lymphocytes is well tolerated.
Sub Study
The goal of this subproject is to see if an imaging procedure called 18FHBG-PET/CT can help
us see if the lymphocytes you received have gone to the sites in the body where the
anti-cancer effects are taking place.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |